ReviewJournal of inorganic biochemistry2026
Mechanistic and spectroscopic characterization of human CYP17A1 in Nanodiscs.
Review in Journal of inorganic biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The human cytochrome P450 CYP17A1 plays a critical role in the production of steroid hormones, converting pregnenolone to dehydroepiandrosterone and progesterone to androstenedione. Sequential reactions catalyzed by CYP17A1 are hydroxylation at C17 position, followed by C17 - C20 carbon‑carbon bond scission. The mechanism of the lyase reaction is still debated, with two proposed reaction pathways favoring either a peroxo- (Compond 0) or iron-oxo (Compound 1) driven catalysis. In this review we summarize the results obtained through collaboration between the Sligar laboratory at University of Illinois and the Kincaid laboratory at Marquette University over the last 15 years. We used a combination of spectroscopic and functional studies of human CYP17A1 incorporated in lipid Nanodiscs, mimicking the native membrane environment, to dissect the elementary steps of P450 reaction cycle and characterize the iron‑oxygen intermediates in the presence of substrates for both reactions catalyzed by CYP17A1. In addition, we used the mutations E305G and T306A to probe the effect of perturbing the proton delivery required for the formation of Compound 1, but not for Compound 0, and the mutation N202S involved in substrate positioning at the active site. Resonance Raman spectra, in combination with cryo-radiolytic reduction of the oxy-complex of CYP17A1, provided a detailed picture of hydrogen bonding and protonation of peroxo- and hydroperoxo- intermediates and identified a new transient hemiketal complex on the peroxo-driven pathway of lyase reaction. These results consistently demonstrated the predominant role of the peroxo-driven catalysis for the lyase reaction in CYP17A1 incorporated in lipid Nanodiscs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.